US2009209575A1PendingUtilityA1

Method for treating neuropathic pain and associated syndromes

46
Individually held — no corporate assignee on recordPriority: Dec 6, 2004Filed: Apr 17, 2009Published: Aug 20, 2009
Est. expiryDec 6, 2024(expired)· nominal 20-yr term from priority
Inventors:Kirk W. JohnsonLance SultzbaughJennifer Shumilla
A61P 31/18A61P 9/10A61P 31/22A61P 35/00A61P 43/00A61P 25/08A61P 25/02A61P 25/00A61P 29/00A61P 25/04A61K 31/4745A61P 21/00A61K 31/437
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to the use of ibudilast for treating neuropathic pain.

Claims

exact text as granted — not AI-modified
1 - 19 . (canceled) 
   
   
       20 . A method of treating a mammalian subject suffering from existing neuropathic pain, wherein said subject does not have multiple sclerosis, said method comprising administering to said subject a therapeutic dosage of ibudilast, whereby as a result of said administering, the subject experiences relief of said neuropathic pain, and wherein no ibudilast is administered prior to the onset of neuropathic pain symptoms. 
   
   
       21 . The method of  claim 20 , wherein said subject is administered an initial therapeutic dosage of 1-200 mg/day of ibudilast. 
   
   
       22 . The method of  claim 20 , wherein said subject is administered an initial therapeutic dosage of 30-300 mg/day of ibudilast. 
   
   
       23 . The method of  claim 20 , wherein said subject is administered an initial therapeutic dosage of 30-200 mg/day of ibudilast. 
   
   
       24 . The method of  claim 20 , wherein said subject is administered an initial therapeutic dosage of 1-60 mg/day of ibudilast. 
   
   
       25 . The method of  claim 20 , wherein said subject is administered an initial therapeutic dosage of 40 mg/day of ibudilast. 
   
   
       26 . The method of  claim 20 , wherein said subject is administered an initial therapeutic dosage of 60 mg/day of ibudilast. 
   
   
       27 . The method of  claim 20 , wherein said subject is administered an initial therapeutic dosage of 80 mg/day of ibudilast. 
   
   
       28 . The method of  claim 20 , wherein said subject suffers from postherpetic neuralgia, trigeminal neuralgia, and neuropathic pain associated with a condition selected from the group consisting of herpes, HIV, traumatic nerve injury, stroke, post-ischemia, fibromyalgia, reflex sympathetic dystrophy, complex regional pain syndrome, spinal cord injury, sciatica, phantom limb pain, diabetic neuropathy, and cancer chemotherapeutic-induced neuropathic pain. 
   
   
       29 . The method of  claim 20 , wherein said administering comprises once daily dosing. 
   
   
       30 . The method of  claim 20 , wherein said administering comprises twice or thrice daily dosing. 
   
   
       31 . The method of  claim 20 , wherein said administering is over a time course of at least about a week. 
   
   
       32 . The method of  claim 20 , wherein said administering is over a time course ranging from about one week to 50 weeks. 
   
   
       33 . The method of  claim 20 , whereby said subject is experiencing allodynia, and said administering is effective to relieve allodynia experienced by said subject. 
   
   
       34 . The method of  claim 20 , wherein said administering is effective to attenuate neuropathic pain experienced by said subject for up to at least 16 hours post ibudilast administration. 
   
   
       35 . The method of  claim 20 , wherein said administering step comprises administering ibudilast in combination with an additional agent effective for treating neuropathic pain. 
   
   
       36 . The method of  claim 35 , wherein said additional agent is selected from the group consisting of gabapentin, memantine, pregabalin, morphine and related opiates, cannabinoids, tramadol, lamotrigine, lidocaine, carbamazepine, duloxetine, milnacipran, and tricyclic antidepressants. 
   
   
       37 . A method of treating a mammalian subject suffering from existing neuropathic pain, said method comprising administering to said subject an initial therapeutic dosage of greater than 60 mg/day of ibudilast, whereby as a result of said administering, the subject experiences relief of said neuropathic pain, wherein no ibudilast is administered prior to the onset of neuropathic pain symptoms. 
   
   
       38 . The method of  claim 37 , wherein said subject is administered an initial therapeutic dosage of 80 mg/day. 
   
   
       39 . The method of  claim 37 , wherein said subject suffers from postherpetic neuralgia, trigeminal neuralgia, and neuropathic pain associated with a condition selected from the group consisting of herpes, HIV, traumatic nerve injury, stroke, post-ischemia, fibromyalgia, reflex sympathetic dystrophy, complex regional pain syndrome, spinal cord injury, sciatica, phantom limb pain, diabetic neuropathy, and cancer chemotherapeutic-induced neuropathic pain. 
   
   
       40 . The method of  claim 37 , wherein said administering step comprises systemically administering ibudilast. 
   
   
       41 . The method of  claim 40 , wherein said ibudilast is administered by a route selected from oral, intravenous, subcutaneous, intramuscular, intraperitoneal, intranasal, and sublingual. 
   
   
       42 . The method of  claim 37 , wherein said administering step comprises centrally administering ibudilast by a route selected from intrathecal, intraspinal and intranasal. 
   
   
       43 . The method of  claim 37 , wherein said administering comprises once daily dosing. 
   
   
       44 . The method of  claim 37 , wherein said administering comprises twice or thrice daily dosing. 
   
   
       45 . The method of  claim 37 , wherein said administering is over a time course of at least about a week. 
   
   
       46 . The method of  claim 37 , wherein said administering is over a time course ranging from about one week to 50 weeks. 
   
   
       47 . The method of  claim 37 , whereby said subject is experiencing allodynia, and said administering is effective to relieve allodynia experienced by said subject. 
   
   
       48 . The method of  claim 37 , wherein said administering is effective to attenuate neuropathic pain experienced by said subject for up to at least 16 hours post ibudilast administration. 
   
   
       49 . The method of  claim 37 , wherein said administering step comprises administering ibudilast in combination with an additional agent effective for treating neuropathic pain. 
   
   
       50 . The method of  claim 49 , wherein said additional agent is selected from the group consisting of gabapentin, memantine, pregabalin, morphine and related opiates, cannabinoids, tramadol, lamotrigine, lidocaine, carbamazepine, duloxetine, milnacipran, and tricyclic antidepressants. 
   
   
       51 . A method of treating and/or preventing neuropathic pain in a subject with cancer that is undergoing or will undergo cancer chemotherapy, said method comprising administering to said subject a therapeutic dosage of ibudilast. 
   
   
       52 . The method of  claim 51 , wherein the cancer chemotherapy is a taxol, vinblastine, or vincristine chemotherapy.

Join the waitlist — get patent alerts

Track US2009209575A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.